Data Sheet (Cat.No.T14348)



Auristatin E

Chemical Properties

CAS No.: 160800-57-7


Formula: C40H69N5O7

Molecular Weight: 732.01

Appearance: no data available

Storage: keep away from moisture

Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

| Description | Auristatin E, a cytotoxic tubulin modifier, disrupts cell division by inhibiting tubulin polymerisation. This compound demonstrates potent and selective antitumor activities, serving as an MMAE analog and cytotoxin in antibody-drug conjugates. |
|---------------|---|
| Targets(IC50) | Microtubule Associated,ADC Cytotoxin |

Solubility Information

| Solubility | DMSO: 60 mg/mL (81.97 mM),Sonication is recommended. |
|------------|---|
| | (< 1 mg/ml refers to the product slightly soluble or insoluble) |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|-----------|-----------|
| 1 mM | 1.3661 mL | 6.8305 mL | 13.661 mL |
| 5 mM | 0.2732 mL | 1.3661 mL | 2.7322 mL |
| 10 mM | 0.1366 mL | 0.6831 mL | 1.3661 mL |
| 50 mM | 0.0273 mL | 0.1366 mL | 0.2732 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Francisco JA, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102(4):1458-65.

Li D, et al. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma. Mol Cancer Ther. 2013 Jul;12(7):1255-65.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street, Wellesley Hills, MA 02481

Page 1 of 1 www.targetmol.com